A circulating lupus-like coagulation inhibitor induced by chlorpromazine.
A variety of immune phenomena have been associated with chlorpromazine. One such factor, the lupus-like anticoagulant, while nonspecific, has been reported in 26 to 75% of chronic chlorpromazine recipients, although the exact incidence is unknown and requires further investigation. Such patients may have an enhanced risk of bleeding profiles (hemophilia-like) or, conversely, thrombotic events. A case of such a lupus-like anticoagulant with a circulating inactivator of coagulation is discussed in light of the recent literature.
D001778:Blood Coagulation Disorders / Q000139:chemically induced*; D001779:Blood Coagulation Factors / Q000032:analysis / Q000037:antagonists & inhibitors* / Q000302:isolation & purification; D002746:Chlorpromazine / Q000009:adverse effects*; D006801:Humans; D016682:Lupus Coagulation Inhibitor; D008297:Male; D008875:Middle Aged; D010314:Partial Thromboplastin Time
D001779:Blood Coagulation Factors; D016682:Lupus Coagulation Inhibitor; D002746:Chlorpromazine